Trial Profile
A Randomized Multicenter Phase II/III Study Comparing 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced Resectable Adenocarcinoma of the Esophagogastreal Junction or the Stomach - FLOT
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 20 Jun 2019
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Oxaliplatin (Primary) ; Capecitabine; Cisplatin; Epirubicin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 18 Jun 2019 Status changed from active, no longer recruiting to completed.
- 15 Jun 2019 This trial has been completed in Germany, according to European Clinical Trials Database.
- 15 Apr 2019 Results assessing efficacy of Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma published in the Internet Document